According to FutureWise analysis the market for Molecular Cytogenetics in 2023 is US$ 3.07 billion, and is expected to reach US$ 6.73 billion by 2031 at a CAGR of 10.32%.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Molecular Cytogenetics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Molecular Cytogenetics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
The increasing prevalence of genetic disorders, improving healthcare infrastructure, increased adoption of molecular cytogenic products in research and clinical laboratories, pharmaceutical and biotech companies and academic institutes and increased emphasis on targeted treatment of cancer are some of the crucial factors responsible for the growth of the market. The cytogenic analysis earlier focused only on investigating the cellular aspects that detected the genomic aberrations and studying the structure of chromosome in heredity conditions. Currently, cytogenic analysis is being extensively used for applications others than identifying a genome’s chromosomal status, which has enhanced the study of changes in the chromosome involved in the pathogenesis of a disease, the human genome organization in three dimensions.
Human genetics is prominently used for bridging the gap between the provisions of a refined medical service and the applications of findings of genes. Such a broad range of applications shall augment the market growth. Additionally, the rising prevalence of cancer and increased mortality rate annually has substantially helped in the molecular cytogenetics market growth. Such a consistent rise in new cancer cases has increased the necessity for developing novel technologies for a completer understanding of cancer genomically. Some of the recognised cytogenic methods like Comparative Genomic Hybridization and FISH that offer extensive insights about the molecular signatures related to cancer, thereby gaining information on the progression of cancer. Increased pharmacogenomic activities are predicted to substantially influence the proliferation of the market. However, the reimbursement policies for molecular cytogenetics are unfavourable and these instruments being expensive, the treatments are meant to be expensive as well, thereby negatively affecting the growth of the market.